Chiesi Group Signs Exclusive Licence Agreement with Aliada Therapeutics to Advance Blood–Brain Barrier Technology for Lysosomal Storage Disorders
Thursday, November 13, 2025
Chiesi Group has entered into an exclusive licence agreement with Aliada Therapeutics, a wholly owned subsidiary of AbbVie, to develop blood–brain barrier (BBB)-crossing platform technology for treating lysosomal storage disorders (LSD). The partnership aims to address neurological and cognitive symptoms associated with these rare conditions, which currently have limited treatment options.
Under the agreement, Chiesi Group will receive a global, exclusive, royalty-bearing licence to develop and commercialise specific enzyme replacement therapies based on Aliada’s proprietary BBB-crossing technology. Aliada will receive an upfront payment and will be eligible for additional milestone and sales-based payments, along with tiered royalties on future sales. Chiesi Group will oversee and fund all research, development, and commercialisation activities worldwide.
The collaboration builds on a research partnership established in August 2023, which explored multiple enzyme cargoes modified with Aliada’s MODEL™ platform. This platform leverages natural brain endothelial transport pathways to enable large-molecule therapeutics to cross the BBB efficiently.
Through this agreement, both companies aim to advance the development of innovative therapies capable of addressing the underlying neurological challenges of lysosomal storage disorders, moving beyond symptom management to improve long-term patient outcomes.
Source: globenewswire.com
